An innovator in donor organ preservation. FDA clearance/ CE marked for all solid organ transplants. #Paragonix #hearttransplant #heartfailure #cardiac
Mentions in press and media 14
| Date | Title | Description |
| 23.04.2025 | Getinge's Strong Start to 2025: Navigating Challenges with Resilience | Getinge, a prominent player in the medtech industry, has kicked off 2025 with a robust performance, showcasing resilience amid global challenges. The company reported a 6.2% organic growth in net sales for the first quarter, alongside a 2.9... |
| 22.04.2025 | Getinge Interim Report January-March 2025: Strong sales and improved earnings – continued focus on customer value and profitability going forward | Getinge Interim Report January-March 2025: Strong sales and improved earnings – continued focus on customer value and profitability going forward Tue, Apr 22, 2025 12:00 CET Report this content “We are entering 2025 with healthy organic sal... |
| 22.04.2025 | Getinge Interim Report January-March 2025: Strong sales and improved earnings - continued focus on customer value and profitability going forward | GOTHENBURG, Sweden, April 22, 2025 /PRNewswire/ -- "We are entering 2025 with healthy organic sales growth and improved adjusted operating profit despite headwinds from currency effects," says Mattias Perjos, President & CEO a... |
| 30.01.2025 | Getinge to phase out its surgical perfusion business | Getinge has initiated a gradual phaseout of its surgical perfusion business, to focus on more profitable growth areas such as extracorporeal life support (ECLS) and transplant care. During a Jan. 28 earnings call, Getinge CEO Mattias Vadste... |
| 29.01.2025 | Getinge's Resilient Surge: A Year of Record Sales and Strategic Shifts | In the world of healthcare technology, Getinge has emerged as a formidable player. The company’s Year End Report for 2024 paints a picture of resilience and growth. With record sales and a robust order intake, Getinge is riding a wave of su... |
| 28.01.2025 | Getinge Year End Report 2024: Strong order intake and increased sales contributed to sharp improvement in margins | GOTHENBURG, Sweden, Jan. 28, 2025 /PRNewswire/ -- "In 2024, Getinge had record sales and we finished off the year with a strong quarter. Both order intake and net sales increased significantly, also organically, with positive performan... |
| 28.01.2025 | Getinge Year End Report 2024: Strong order intake and increased sales contributed to sharp improvement in margins | Getinge Year End Report 2024: Strong order intake and increased sales contributed to sharp improvement in margins Tue, Jan 28, 2025 08:00 CET Report this content “In 2024, Getinge had record sales and we finished off the year with a strong ... |
| 28.10.2024 | Paragonix Technologies receives FDA 510(k) clearance for KidneyVault portable renal perfusion system | Paragonix Technologies receives FDA 510(k) clearance for KidneyVault portable renal perfusion system Mon, Oct 28, 2024 17:05 CET Report this content Paragonix Technologies, a leading organ preservation company recently acquired by Getinge, ... |
| 18.10.2024 | Getinge Interim Report July-September 2024: Strong order intake but temporary delivery disruptions had a negative impact on earnings | Getinge Interim Report July-September 2024: Strong order intake but temporary delivery disruptions had a negative impact on earnings Fri, Oct 18, 2024 08:00 CET Report this content “The order intake increased by 10.0%, of which organic grow... |
| 18.10.2024 | Getinge Interim Report July-September 2024: Strong order intake but temporary delivery disruptions had a negative impact on earnings | GOTHENBURG, Sweden, Oct. 18, 2024 /PRNewswire/ -- "The order intake increased by 10.0%, of which organic growth was 7.4%. All regions reported a positive performance," says Mattias Perjos, President & CEO at Getinge. The medte... |
Show more